Novel putative pharmacological therapies to protect the right ventricle in
pulmonary hypertension: a review of current literature
#MMPMID28099680
Maarman GJ
; Schulz R
; Sliwa K
; Schermuly RT
; Lecour S
Br J Pharmacol
2017[Apr]; 174
(7
): 497-511
PMID28099680
show ga
Pulmonary hypertension (PH) is defined by elevated mean pulmonary artery pressure
following the pathological remodelling of small pulmonary arteries. An increase
in right ventricular (RV) afterload results in RV hypertrophy and RV failure. The
pathophysiology of PH, and RV remodelling in particular, is not well understood,
thus explaining, at least in part, why current PH therapies have a limited
effect. Existing therapies mostly target the pulmonary circulation. Because the
remodelled RV fails to support normal cardiac function, patients eventually
succumb from RV failure. Developing novel therapies that directly target the
function of the RV may therefore benefit patients with PH. In the past decade,
several promising studies have investigated novel cardioprotective strategies in
experimental models of PH. This review aims to comprehensively discuss and
highlight these novel experimental approaches to confer, in the long-term,
greater health benefit in patients with PH.
free
free
free
